5-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]thiophene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: 5-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]thiophene
• 化学式: C₈H₁₄S
• 分子量: 142.26
• InChiKey: VLJHHLOSBQNBGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] MODULATORS OF P97 AAA ATPASE ACTIVITY<br/>[FR] MODULATEURS DE L'ACTIVITÉ DE L'ATPASE P97 AAA
  申请人：UNIV OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：WO2017197080A1

  公开（公告）日：2017-11-16

  The present invention is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by modulation or inhibition of p97.

  本发明涉及抑制或调节p97的方法，以及在这些方法中有用的化合物和组合物。可以用本发明的化合物和组合物治疗的疾病和病症包括但不限于癌症和易受p97调节或抑制治疗的神经退行性疾病。
• [EN] 1,2,3-TRIAZOLE INHIBITORS OF P97 AAA ATPASE ACTIVITY<br/>[FR] INHIBITEURS DE 1,2,3-TRIAZOLE DE L'ACTIVITÉ AAA ATPASE DE P97
  申请人：UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION

  公开号：WO2019200032A1

  公开（公告）日：2019-10-17

  The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by modulation of p97.

  本技术旨在提供一种抑制或调节p97的方法以及在这些方法中有用的化合物和组合物。可以用本技术的化合物和组合物治疗的疾病和病况包括但不限于抗菌感染、抗病毒感染、癌症和神经退行性疾病，这些疾病可以通过调节p97来进行治疗。
• BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETALACTAMASE INHIBITORS
  申请人：NAEJA PHARMACEUTICAL INC.

  公开号：US20140221341A1

  公开（公告）日：2014-08-07

  A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR 1 or NR 2 R 3 , and R 1 , R 2 , R 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  化合物的式子(I)：其中：M是氢或药用可接受的盐形成阳离子；Y是OR1或NR2R3，而R1、R2、R3和M的定义如本文所述。此外，还提供了治疗细菌感染的方法、制药组合物、分子复合物和制备化合物的过程。
• PYRIDONE DERIVATIVE, COMPOSITION THEREOF AND APPLICATION THEREOF AS ANTI-INFLUENZA DRUG
  申请人：Jiangxi Caishi Pharmaceutical Technology Co., Ltd.

  公开号：EP3753936A1

  公开（公告）日：2020-12-23

  The present disclosure belongs to the field of medicinal chemistry, and relates to a novel pyridone derivative represented by Formula (I) or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and use thereof in the preparation of a drug for preventing or treating diseases such as influenza type A viral infection and/or influenza type B viral infection, particularly use thereof as a PA subunit cap-dependent endonuclease inhibitor for preventing or treating diseases such as influenza type A viral infection and/or influenza type B viral infection. The compounds of the present disclosure have significant activity in inhibiting influenza endonuclease and influenza DNA, can be used either alone or in combination with a neuraminidase inhibitor, a nucleoside drug, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs, significantly shorten the time of influenza infection and reduces mortality, and have excellent clinical application prospects.

  本公开属于药物化学领域，涉及一种由式(I)或其立体异构体代表的新型吡啶酮衍生物、其药学上可接受的盐、溶液或晶体，及其在制备预防或治疗甲型流感病毒感染和/或乙型流感病毒感染等疾病的药物中的用途，特别是其作为预防或治疗甲型流感病毒感染和/或乙型流感病毒感染等疾病的PA亚基帽依赖性内切酶抑制剂的用途。本公开的化合物在抑制流感内切酶和流感DNA方面具有显著活性，可单独使用，也可与神经氨酸酶抑制剂、核苷类药物、PB2抑制剂、PB1抑制剂、M2抑制剂或其他抗流感药物联合使用，可显著缩短流感感染时间，降低死亡率，具有良好的临床应用前景。
• Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
  申请人：FEDORA PHARMACEUTICALS INC.

  公开号：US10030019B2

  公开（公告）日：2018-07-24

  A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  式 (I) 的化合物： 其中 M 是氢或药学上可接受的成盐阳离子； Y 是 OR1 或 NR2R3、 以及 R1、R2、R3 和 M 如本文所定义。此外，还有治疗细菌感染的方法、药物组合物、分子复合物和制备化合物的工艺。